The diagnosis and management of retinal and neurological diseases requires functional assessment of the visual fields. Conventional visual field test devices (perimeters) use behavioral responses from patients and suffer from high rates of quality control failures and poor reproducibility. The NuCoria Field Analyzer (nCFA) has been developed over several years by a team at the ANU who have previously commercialised a popular perimeter.

A significant number of papers have been published on the nCFA method, showing its utility in the major blinding diseases and some neurological problems (see attached). The nCFA directly assesses responses of the visual nervous system to provide objective, non-contact, measurement of the visual fields of both eyes concurrently.
**The Results**

Perimetry is traditionally used in the diagnosis of glaucoma; however, there is growing evidence that perimetry is important in the diagnosis of retinal diseases such as age-related macular degeneration (AMD) and diabetic retinopathy (DR). Key research by the ANU team has determined that the nCFA can detect early disease effects in AMD and DR patients’ eyes before traditional diagnostic tools. Earlier diagnosis enables clinicians to treat patients more effectively with existing therapies and improve patient outcomes.

The nCFA is now at an advanced prototype stage and FDA market approval has been obtained on the basis of substantial equivalence with a marketed perimeter (Class I #K063310).

**The IP & Patents**

Key intellectual property has been created and protected as appropriate including:
- patents (6 patent families) relating to the visual stimuli
- clinical data and normative database
- software
  - pupil tracking
  - patient record management
- hardware
  - product engineering and design specifications
  - regulatory approval dossier and supporting materials
  - user manual

All IP are licensed to NuCoria

---

**EARLY DIAGNOSIS LEADS TO BETTER TREATMENT DECISIONS AND OUTCOMES**

**Comparison of non DR patient with NPDR patients**

See increased sensitivity with NuCoria Perimeter for detection of very early disease (non-proliferative DR) compared with marketed perimeters.
THE NEXT GENERATION OF VISUAL FIELD ANALYZER

PUBLICATIONS


Carle CF, Chain AY, James AC, Kolic M, Maddess T. Comparing structure and function in multifocal pupillographic objective perimetry (mfPOP) and SAP. World Glaucoma Congress 2013.


